Raze

Quick links to important sections

Raze

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Raze

What is Raze? (Azithromycin)

Property Description
Active ingredient Azithromycin (often as dihydrate)
Form Tablet, Capsule, Oral Suspension, IV Solution
Pharmacological class Macrolide Antibiotic (Azalide Subclass)
Common use Combating bacterial infections
Origin Semisynthetic

Defining Raze: Classification and Core Identity

Raze is a prescription-only medication featuring the active ingredient Azithromycin, whose primary function is to serve as an antibiotic against systemic bacterial infections. Azithromycin is a macrolide antibacterial drug and occupies a distinct position as an azalide—a semisynthetic derivative of Erythromycin. This specific chemical modification is clinically recognized for providing the drug with a prolonged half-life and high concentration within tissues. Azithromycin provides an antibacterial effect across various body systems.

Azithromycin Composition and Available Forms

The composition of Raze is centered on the Azithromycin substance, formulated alongside necessary pharmaceutical excipients in a single-ingredient product. The medication is available in various forms for systemic delivery, including solid oral preparations like tablets and capsules, liquid formulations such as oral suspension often used for the pediatric patient group, and sterile solutions for intravenous injection. These preparations ensure flexibility in administration via the oral and intravenous routes, facilitating the reliable delivery of the active compound to the site of infection.

General Purpose of Azithromycin

The overarching purpose of Azithromycin is to act as an effective anti-infective agent to control bacterial infections caused by susceptible microorganisms. Its therapeutic action is achieved by interfering with the bacteria’s capacity to synthesize essential proteins, which results in a bacteriostatic effect that halts microbial replication. The drug is frequently prescribed in scenarios, such as the management of respiratory tract infections, where its favorable tissue penetration profile is advantageous. Consequently, this drug offers a reliable tool for controlling the proliferation of pathogenic bacteria and assisting the body in resolving the infectious process.

Regulatory References

  1. NIH DailyMed Azithromycin Monograph
  2. NIH MedlinePlus

What side effects are possible with Raze?

Possible side effects and safety information

The safety profile of Raze (Azithromycin) is officially categorized by regulatory bodies, outlining both expected reactions and rare, serious risks. Adverse reactions are grouped by System-Organ Class (SOC) and frequency, adhering to government-mandated standards for communicating risk.


Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Very Common Gastrointestinal disturbances, including diarrhea, abdominal pain, and nausea, are listed as very common in regulatory documents.
Common Central nervous system effects such as headache and dizziness, along with skin rash and arthralgia (joint pain), are classified as common.
Serious Adverse Reactions Officially documented serious reactions include severe hepatotoxicity (sometimes fatal), life-threatening QT interval prolongation and Torsades de Pointes, and severe systemic hypersensitivity reactions like SJS, TEN, and DRESS. Clostridioides difficile-Associated Diarrhea (CDAD) is also a documented risk.

Population-Specific and Time-Related Safety Notes

The official labeling defines specific safety considerations for vulnerable groups. Geriatric patients may have an increased susceptibility to the risk of Torsades de Pointes arrhythmias. Reports of Infantile Hypertrophic Pyloric Stenosis (IHPS) are documented following use in neonates (up to 42 days old). For individuals with severe renal impairment, caution is necessary due to potential increases in systemic exposure.

Safety patterns tied to exposure duration are also noted. Serious allergic symptoms may recur in some patients even after the medication is discontinued. Furthermore, CDAD can reportedly occur up to two months after the use of the medicine.


Safety Restrictions

Azithromycin is contraindicated in individuals with known hypersensitivity to the drug or any macrolide/ketolide drug. It is also contraindicated in patients with a prior history of cholestatic jaundice or hepatic dysfunction associated with previous Azithromycin exposure, reflecting specific limitations defined in regulatory documents.

Overdose and Emergency Response

In the event of an acute overdose of Raze (Azithromycin), the official regulatory profile indicates that manifestations are generally an exaggeration of the drug's known adverse reactions. Documented clinical presentations primarily include severe gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. Additionally, ototoxicity (hearing disturbances) has been noted in the official labeling from national medicine authorities.

The most significant risk in overdose relates to the cardiovascular system. Official documents emphasize that Azithromycin carries the potential for prolonging the QT interval, which can lead to a serious and potentially fatal cardiac arrhythmia known as Torsades de Pointes.

Immediate Emergency Action Required

Regulators mandate that in any suspected case of overdose, immediate emergency medical care must be sought. If severe, life-threatening symptoms are present, such as collapse, seizure, trouble breathing, or inability to be awakened, emergency services must be called at once. Treatment for an overdose is defined as general symptomatic and supportive measures, as no specific antidote is known in the regulatory documents. Supportive steps may include the administration of activated charcoal to limit drug absorption, and hospital monitoring may be required to observe and manage the potential cardiovascular effects.

Therapeutic Uses of Raze

Raze is a macrolide antibacterial generally used in situations involving certain distressing symptoms caused by susceptible bacteria. Its use is considered relevant across therapeutic domains involving infections of the ears, lungs, sinuses, throat, skin, and reproductive organs.

Symptom Relief Across Key Domains

The medication is commonly used across conditions presenting with acute episodes, including pneumonia, sinusitis, otitis media, and specific skin or genitourinary infections. Raze may assist with managing symptom clusters that may become intense or disruptive, such as persistent cough, ear pain, swelling, and discharge associated with acute or disruptive episodes. This supportive therapeutic benefit helps maintain a sense of stability and contributes to easing the overall symptom load during periods of heightened discomfort.

“Raze is applied in settings where short-term symptomatic assistance is needed to assist with managing symptoms related to inflammatory or irritative states.”

The drug is relevant for managing conditions that involve recurrent or episodic manifestations. It is applied in addressing symptomatic needs in prophylactic contexts, particularly for infections like Disseminated Mycobacterium avium Complex (MAC) in vulnerable patient groups.


Quick Fact: Relief for Respiratory Discomfort

Raze is commonly used to help with acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia, supporting patients during episodes of heightened discomfort by supporting the management of symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Raze?

This section outlines the official population eligibility rules for Azithromycin (Raze) as defined by regulatory health authorities.


Population Status Eligibility Statement
Contraindicated Patients with known hypersensitivity to any macrolide or ketolide antibiotic, or a history of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use.
Use Restricted Severe hepatic disease and severe renal impairment (GFR < 10 ml/min) require caution or prohibition. Caution is also mandatory for patients with pre-existing cardiac risk factors (e.g., known QT prolongation) or Myasthenia Gravis.
Age-Related Adults and older adults are generally eligible, though older patients may have increased cardiac risk. Safety has not been established in children under 6 months of age. The medicine is not recommended for neonates (treatment up to 42 days of life) due to the reported risk of Infantile Hypertrophic Pyloric Stenosis.
Physiological Status Pregnancy use is permitted only when the regulatory assessment determines the benefit clearly outweighs the potential risk. Lactation requires monitoring of the infant for possible gastrointestinal effects.

This profile establishes clear exclusion criteria and mandates caution for specific patient groups based on known allergies, pre-existing organ function, cardiac risk, and age, strictly following the regulatory label.

What should I know about interactions with other medicines?

Raze's official interaction profile, documented by regulatory authorities, details specific pharmacokinetic and pharmacodynamic patterns. The regulatory constraints define which combinations are not recommended, which substances alter drug exposure, and when administration timing must be separated.

Documented Interaction Patterns

Interaction Type Interacting Substance(s) Official Regulatory Outcome
Formal Prohibition Ergot Derivatives (e.g., Ergotamine) Co-administration is not recommended due to the theoretical potential for ergotism.
Pharmacodynamic Risk QT-Prolonging Drugs Co-administration is associated with an increased risk of prolonged cardiac repolarization, which may lead to torsades de pointes.
Exposure Alteration Nelfinavir (Protease Inhibitor) Co-administration significantly increases Azithromycin's Cmax and AUC (overall exposure).
Anticoagulation Effect Warfarin (Anticoagulant) May lead to increased coagulation times; a formal drug-drug interaction is documented.
Absorption & Timing Antacids (Aluminum/Magnesium) Reduces Azithromycin Cmax; administration of the products must be separated by approximately 2 hours.
Food Interaction High-Fat Meal (Tablets/Suspension) Officially documented to increase the Azithromycin Cmax (peak plasma concentration).

Population-Specific Cautions

The interaction structure is further defined by population-specific cautions. Due to the drug's primary elimination route, caution is warranted in patients with hepatic impairment. Additionally, caution is noted for patients with severe renal impairment (GFR < 10 mL/min) because of documented increases in Azithromycin exposure in this population.

Mechanism of Action

Inhibition of Bacterial Protein Synthesis

Azithromycin primarily acts by targeting the bacterial components required for growth. The molecule establishes a high-affinity, non-covalent bond with the 23S ribosomal RNA of the bacterial 50S ribosomal subunit, creating a steric blockade within the polypeptide exit tunnel. This molecular interference halts the elongation of essential protein chains, which results in the arrest of bacterial proliferation (bacteriostasis), thereby modulating the overall bacterial count.


Secondary Modulation of Host Inflammatory Pathways

Beyond this direct antibacterial function, the drug engages mechanisms within the host’s immune system. Azithromycin modulates key host inflammatory mediators, such as certain pro-inflammatory cytokines, reducing their release and activity in affected tissues. This ancillary mechanism alters the host's physiological response to inflammation, contributing to the full spectrum of its known pharmacodynamic activity.


Functional Constraints of Resistance Mechanisms

The inhibitory action is functionally limited when bacteria acquire defense systems like active efflux pumps or methylase enzymes (e.g., erm gene products), which either expel the molecule or chemically modify the target binding site. These constraints prevent the necessary inhibitory action, overriding the consequential physiological effect.

Dosage and Administration Information

Raze (Azithromycin) is administered systemically via the oral route or as an intravenous (IV) infusion. The official administration protocols define precise dosage schedules and specific handling constraints based on the formulation used.

The standard adult usage patterns involve short courses, such as a 5-day regimen (500 mg on Day 1, followed by 250 mg daily) or a 3-day course of 500 mg once daily. For specific indications, a single dose of 1 gram or 2 grams may be used. Dosage for the pediatric population is determined by body weight (mg/kg) to ensure proper administration.

Administration requires adherence to specific timing rules. Standard oral preparations, including tablets and suspension, may be consumed with or without food. However, the extended-release oral suspension must be taken on an empty stomach, at least one hour before or two hours after a meal. Furthermore, official instructions direct that antacids containing magnesium or aluminum must not be consumed simultaneously; a separation of approximately two hours is required.

The IV formulation is limited to a slow infusion, typically 500 mg once daily, and is explicitly restricted from being given as a rapid injection or administered intramuscularly. The IV therapy is frequently used as a step-down approach, followed by oral dosing to complete a total treatment course.

Recent Clinical Evidence

Research evidence / Overview of studies for Raze (Azithromycin)


Evidence for Infections of the Lungs, Sinuses, and Ears

This section summarizes the research framework for Raze (Azithromycin) in common infections such as community-acquired pneumonia, sinusitis, and otitis media. The evidence base relies heavily on Randomized Controlled Trials (RCTs) and meta-analyses that have monitored patients to describe how symptoms and infection markers evolve over a defined time interval. This research helps show what has been observed so far regarding the management of these bacterial conditions.

Research on Community-Acquired Pneumonia and Acute Bronchitis

Studies conducted during periods of increased symptom activity, such as acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia, primarily consisted of short-term RCTs. These trials examined outcomes capturing phases of heightened symptom activity, including outcomes monitoring physiological strain or stress, and hospitalization rates. Regulatory summaries describe the research base used for evaluating these bacterial infections. Long-term outcomes, such as the persistence of changes or the long-term recurrence rate following therapy, are not fully established.

Research on Sinus and Ear Infections

Evidence for use in infections like sinusitis and otitis media also primarily comes from RCTs and comparative studies, often including the pediatric patient group. These trials explored outcomes related to physical discomfort, such as ear pain or sinus swelling, alongside measurements of bacteriological markers. For otitis media, studies focused on monitored outcomes related to clinical resolution and outcomes related to microbiological markers. Comparative evidence against alternative treatments for various subgroups can be limited.


Evidence for Specific Preventative Uses

Raze was evaluated in long-term RCTs and observational cohort studies for specific preventative applications. The research examined its use for the prophylaxis of Disseminated Mycobacterium avium Complex (MAC) in specific vulnerable groups. Studies focused on monitored outcomes reflecting daily functioning or activity level over extended periods. The findings describe patterns observed in these studies related to the incidence rate of MAC infection and hospitalization in the specific high-risk cohorts.

Understanding the Remaining Research Gaps

Despite the significant evidence base for Raze, the concluding research summaries clarify several aspects where data are still emerging or where the certainty remains low. The primary gap involves the limited information for long-term outcomes across many of its common uses, as most research was designed for short-term monitoring of acute resolution. Research is ongoing to fully characterize the clinical implications of increasing antibiotic resistance globally, as this dynamic factor may necessitate adjustments to its application parameters.

Key Studies & References

  1. Disseminated Mycobacterium avium Complex: Adult and Adolescent Opportunistic Infections Guidelines (HIV.gov/NIH)
  2. Comparative evaluation of 2g single dose versus conventional dose azithromycin in uncomplicated skin and skin structure infections
  3. A Systematic Review and Meta-Analysis of Efficacy and Safety of Azithromycin Versus Moxifloxacin for the Initial Treatment of Mycoplasma genitalium Infection

Frequently Asked Questions (FAQ)

Common questions about Raze (FAQ)


Q: Is Raze considered a long-term or short-term treatment?

The drug is typically described in official documents as being used for short-term treatment courses, such as 3-day or 5-day regimens, for managing acute infections. However, the medicine has also been studied and described for long-term preventative use for specific infections in certain patient groups.


Q: Does Raze contain any type of steroid?

According to the official product information, the active ingredient in Raze is Azithromycin, which is an antibiotic. The official components and pharmaceutical classification confirm that the medicine is an antibacterial drug and does not contain any steroid components.


Q: How quickly does Raze typically start to have a noticeable effect?

Evidence summarized in official patient information indicates that symptom improvement for most infections is commonly described as occurring within a few days of starting treatment. The length of time depends on the specific infection being managed.


Q: How long does the effect of a single dose of Raze last?

The drug is recognized for its prolonged half-life, which is the time it takes for half of the substance to leave the body. The active substance is documented to remain in the tissues for an extended period, which is noted to contribute to the medicine’s lasting action.


Q: Is it common to feel tired or drowsy after taking Raze?

Official safety documents list dizziness and headache as common effects of the drug. Feelings of fatigue or somnolence (drowsiness) are also noted to be reported as side effects in official documents.


Q: What happens if a person misses a dose of Raze?

Official guidance defines the process: if a dose is missed when taking a multiple-dose regimen, it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the user is directed to continue the regular schedule and is advised not to take an extra dose to make up for the missed one.


Q: Is Raze still effective if I take it without food?

The effectiveness of standard Raze tablets and suspensions is documented to be non-dependent on being taken with or without food. However, it is important to note that the extended-release oral suspension must be taken on an empty stomach.


Q: Are there any specific activities, like driving, that are restricted while taking Raze?

The official labeling advises caution when performing skilled tasks such as driving or operating machinery. This caution applies particularly if the individual experiences effects like dizziness or headache, which are documented side effects of the medicine.


Q: What should I do if I experience a very rare but severe side effect listed on the label?

Regulatory documents state that for rare but serious effects listed in the product labeling, individuals are directed to seek emergency medical attention or to contact a healthcare professional immediately.


Q: Is Raze appropriate for use by elderly patients?

Older adults are generally eligible for use. However, official information notes that this population may have an increased cardiac risk, specifically regarding a serious irregular heart rhythm (Torsades de Pontes).


Q: Were the clinical trials for Raze published in major medical journals?

The research base used for the drug's evaluation includes Randomized Controlled Trials and meta-analyses. Regulatory communications have, at times, made reference to studies published in recognized medical journals.


Q: Does the official information list any known links between Raze and sleep problems?

Official safety data has noted that disturbances such as sleep problems (insomnia) and sleepiness (somnolence) have been reported as uncommon or rare side effects in post-marketing reports.


Q: Do generic versions of Raze exist and are they considered equivalent?

Generic versions of the active ingredient Azithromycin are available. In the U.S., many of these generic forms are officially classified as therapeutically equivalent (meaning they are expected to work in the same way) to the brand-name product.


Q: Is it safe to take Raze if I also take a medication for blood pressure?

Regulatory documents flag caution for patients with existing cardiac risk factors or those taking medications that may prolong the QT interval. Specific heart and blood pressure medications, such as Digoxin, have documented interactions that are detailed in the official product information.


Q: What kind of research has been done on Raze regarding its effect on acute bronchitis?

Research summaries describe studies on the management of acute bacterial exacerbations of chronic bronchitis. Uncomplicated acute bronchitis is generally managed based on different clinical considerations.


Q: Is Raze the same kind of medicine as [Common similar drug name]?

Raze is classified as a Macrolide Antibiotic and belongs to the Azalide subgroup. This classification indicates that it shares a related chemical structure and general mechanism of action with other drugs in the macrolide class.


Q: How is Raze different from other medicines used for the same purpose?

The drug is characterized by a specific chemical modification that provides it with a prolonged half-life and enables it to achieve a high concentration within tissues.


Q: Can Raze be taken at the same time as common over-the-counter pain relievers?

Regulatory data has not documented a formal pharmacokinetic interaction requiring dose adjustment between Azithromycin and common pain relievers like Acetaminophen or NSAIDs. Other potential interactions are documented in the official labeling.


Q: Does Raze interact with birth control pills?

Official patient information may note that some antibiotics, including macrolides, may potentially lessen the effect of hormonal contraceptives. Official information notes this potential interaction should be reviewed when starting treatment.


Q: Are there any Black Box Warnings or similar major safety alerts associated with Raze?

Regulatory documentation includes a strong warning about the risk of QT interval prolongation and a potentially fatal irregular heart rhythm (Torsades de Pontes) in susceptible patient populations.


Q: Is it normal to feel a bit nauseous when first starting Raze?

Nausea is listed as a very common adverse reaction in the official product information. Mild gastrointestinal effects, including nausea, are frequently reported during the initial days of the treatment course.


Q: Does Raze cause dry mouth or changes in salivation?

Dry mouth and other effects related to the mouth or tongue have been reported as rare or uncommon side effects in post-marketing safety data.


Q: Can Raze be crushed or cut in half?

Official instructions for some solid oral formulations, such as capsules, direct the user to swallow them whole. They are advised not to be cut, broken, or chewed, to ensure the medicine is delivered as intended.


Q: What are the differences between Raze tablets and the syrup or suspension form?

Key differences include the typical patient group for the form (suspension is often used for pediatric patients) and the administration rules. The extended-release suspension must be taken on an empty stomach, while standard tablets can be taken with or without food.

How should Raze be stored and disposed of?

How to Store and Dispose of Raze (Azithromycin)


Official Storage Conditions

Raze (azithromycin) must be stored according to label requirements to ensure stability.

Dosage Form Required Storage Condition
Tablets/Capsules Store at controlled room temperature (20 C to 25 C).
Oral Suspension Store the dry powder below 30 C. The reconstituted liquid is stable for 10 days and must not be frozen.

The medication must be protected from moisture and kept in its original container with the lid tightly closed. It must also be stored out of the sight and reach of children.


Disposal Instructions

Expired or unused Raze should not be disposed of in household waste or flushed down wastewater. Disposal must be carried out in accordance with local requirements for unused pharmaceutical products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Raze found in:

A-Z Index: